Search results

Skip to results

Type

Status

Last updated

Showing 31 to 38 of 38 results for olaparib

  1. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued [GID-TA11033]

    Technology appraisal guidance
    Discontinued

  2. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Technology appraisal guidance
    Published
    2 February 2022

  3. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Technology appraisal guidance
    Published
    28 August 2019

  5. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]

    In development [GID-TA11251] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Technology appraisal guidance
    Published
    27 January 2016

  7. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

    News
    Last updated
    13 June 2024

  8. NICE recommends olaparib for early breast cancer and metastatic prostate cancer

    Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.

    News
    Last updated
    22 January 2024